Portal de Periódicos da CAPES

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia

2015; SAGE Publishing; Volume: 8; Linguagem: Inglês

10.4137/cmbd.s24628

2634-8535

Mohamed A. Yassin, Abbas Moustafa, Abdulqadir J. Nashwan, Ashraf Soliman, Hatim El Derhoubi, Shehab Mohamed, Deena Mudawi, Sarah Elkourashy, Deena-Raiza Asaari, Hope-Love G. Gutierrez, Radwa M. Hussein, Mohamed Al Musharraf, Samah Kohla, Ahmed M. El‐Sayed, Nader Al‐Dewik,

Bone health and treatments

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia (Ph) chromosome resulting from the reciprocal translocation t(9;22)(q34;q11). The molecular consequence of this translocation is the generation of the BCR-ABL fusion gene, which encodes a constitutively active protein tyrosine kinase. The oncogenic protein tyrosine kinase, which is located in the cytoplasm, is responsible for the leukemia phenotype through the constitutive activation of multiple signaling pathways involved in the cell cycle and in adhesion and apoptosis. Avascular necrosis of the femoral head (AVNFH) is not a specific disease. It occurs as a complication or secondary to various causes. These conditions probably lead to impaired blood supply to the femoral head. The diagnosis of AVNFH is based on clinical findings and is supported by specific radiological manifestations. We reported a case of a 34-year-old Sudanese female with CML who developed AVNFH after receiving dasatinib as a second-line therapy. Though the mechanism by which dasatinib can cause avascular necrosis (AVN) is not clear, it can be postulated because of microcirculatory obstruction of the femoral head. To the best of our knowledge and after extensive literature search, this is the first reported case of AVNFH induced by dasatinib in a patient with CML.